Bristol-Myers Squibb/$BMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Primary listing
NYSE
Employees
34,100
Headquarters
Website
BMY Metrics
BasicAdvanced
$92B
18.16
$2.49
0.36
$2.46
5.49%
Price and volume
Market cap
$92B
Beta
0.36
52-week high
$63.33
52-week low
$42.96
Average daily volume
15M
Dividend rate
$2.46
Financial strength
Current ratio
1.207
Quick ratio
1.043
Long term debt to equity
263.48
Total debt to equity
291.549
Dividend payout ratio (TTM)
98.12%
Interest coverage (TTM)
6.36%
Profitability
EBITDA (TTM)
19,137
Gross margin (TTM)
73.92%
Net profit margin (TTM)
10.58%
Operating margin (TTM)
26.45%
Effective tax rate (TTM)
23.18%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
8.33%
Return on equity (TTM)
29.32%
Valuation
Price to earnings (TTM)
18.158
Price to revenue (TTM)
1.922
Price to book
5.27
Price to tangible book (TTM)
-3.57
Price to free cash flow (TTM)
6.289
Free cash flow yield (TTM)
15.90%
Free cash flow per share (TTM)
7.178
Dividend yield (TTM)
5.45%
Forward dividend yield
5.49%
Growth
Revenue change (TTM)
2.57%
Earnings per share change (TTM)
-177.23%
3-year revenue growth (CAGR)
0.39%
10-year revenue growth (CAGR)
11.28%
3-year earnings per share growth (CAGR)
-6.29%
10-year earnings per share growth (CAGR)
8.79%
3-year dividend per share growth (CAGR)
5.25%
10-year dividend per share growth (CAGR)
5.28%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
Bulls say / Bears say
Q2 2025 revenue rose 1% year-over-year to $12.3 billion, beating the $11.4 billion consensus, and EPS of $1.46 surpassed estimates of $1.07—prompting management to raise full-year revenue guidance to $46.5–$47.5 billion (Reuters).
The growth portfolio delivered $6.6 billion in Q2, up 18% year-over-year driven by Breyanzi, Reblozyl, Camzyos, and Cobenfy, underscoring the success of pipeline diversification in offsetting declines in mature drugs (WSJ).
The $11 billion partnership with BioNTech to co-develop BNT327, a bispecific antibody targeting two cancer cell receptors, bolsters Bristol-Myers Squibb’s immuno-oncology pipeline and positions it to compete with Merck’s Keytruda amid upcoming patent expirations (Financial Times)
The legacy portfolio shrank 14% to $5.67 billion in Q2 2025 due to generic erosion and Medicare Part D reforms, weighing on overall margin improvement (WSJ).
Management cut adjusted EPS guidance to $6.35–$6.65 per share for 2025, down from $6.70–$7.00, after recognizing a $1.5 billion IPR&D charge related to the BioNTech collaboration, highlighting near-term profit headwinds (WSJ).
A U.S. appeals court on Oct 6, 2025 upheld the government’s power under the Inflation Reduction Act to negotiate drug prices—exposing Bristol-Myers Squibb’s top-selling Eliquis to mandatory price cuts beginning in 2026, which could materially reduce future revenues (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Final Trade: GDX, PFE, GFS, BMY
CNBC Television6 days ago
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease
Business Wire7 days ago
Bristol Myers, Takeda to pool data for AI-based drug discovery
Reuters7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $92B as of October 07, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 18.16 as of October 07, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of October 07, 2025, the dividend rate is $2.46 and the yield is 5.49%. Bristol-Myers Squibb has a payout ratio of 98.12% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for November 03, 2025.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.